Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

QUEEN-OSCAR: A Prospective, Multicenter, Single-arm, Phase 2 Study of QL1706 in Combination With Olaparib in Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)

NCT07113964 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT07113964
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07113964 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
QUEEN-OSCAR: A Prospective, Multicenter, Single-arm, Phase 2 Study of QL1706 in Combination With Olaparib in Previously Treated HER2-negative Breast Cancer Patients With Homologous Recombination Deficiency (HRD)
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 2
Overall status
Not yet recruiting
Start date
August 30, 2025
Completion date
March 30, 2029
Enrollment
79 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

previously treated her2-negative breast cancer patients with homologous recombination deficiency